Challenge 3 asks entrants to design a protein that activates the receptor semaglutide and tirzepatide target in diabetes and obesity treatment.
Recap by typeshit. Post by @adaptyvbio on X.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Researchers presenting at the EADV Congress found a clear link, but about half of users had nail issues before treatment. They advise talking to a doctor rather than stopping the drug.
A new episode explores GLP-1 drugs spreading through rush week and an underground weight loss scene on campus.
Loading…